IEQ Capital’s Crescent Biopharma CBIO Stock Holding History

IEQ Capital’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-384	Closed	-$8.06K	–	1896
2025 Q1	$8.06K	Hold	384	–	–	﹤0.01%	1603
2024 Q4	$9.55K	Hold	384	–	–	﹤0.01%	1324
2024 Q3	$6.48K	Hold	384	–	–	﹤0.01%	1155
2024 Q2	$10.8K	Hold	384	–	–	﹤0.01%	1000
2024 Q1	$115K	Hold	384	–	–	﹤0.01%	921
2023 Q4	$90.5K	Hold	384	–	–	﹤0.01%	885
2023 Q3	$57.5K	Hold	384	–	–	﹤0.01%	909
2023 Q2	$66.8K	Hold	384	–	–	﹤0.01%	873
2023 Q1	$48.3K	Hold	384	–	–	﹤0.01%	877
2022 Q4	$116K	Hold	384	–	–	﹤0.01%	764
2022 Q3	$21K	Hold	384	–	–	﹤0.01%	835
2022 Q2	$23K	Hold	384	–	–	﹤0.01%	792
2022 Q1	$44K	Hold	384	–	–	﹤0.01%	803
2021 Q4	$55K	Hold	384	–	–	﹤0.01%	716
2021 Q3	$84K	Hold	384	–	–	﹤0.01%	682
2021 Q2	$89K	Hold	384	–	–	﹤0.01%	602
2021 Q1	$115K	Buy	+384	New	+$138K	﹤0.01%	472

Other funds holding CBIO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

IEQ Capital's CBIO Position: Q2 2025 in Review

IEQ Capital sold out of Crescent Biopharma (CBIO) in Q2 2025, closing a stake of 384 shares — an estimated $8.06K sold.

IEQ Capital first reported a position in CBIO in Q1 2021 and held it in 17 quarters. The position peaked at $116K in Q4 2022. 30 funds tracked by Wall St. Rank hold CBIO as of Q2 2025.

IEQ Capital reported no remaining Crescent Biopharma position as of Q2 2025 after selling out during the quarter.
IEQ Capital sold 384 Crescent Biopharma shares in Q2 2025, an estimated $8.06K.
IEQ Capital first reported a position in Crescent Biopharma in Q1 2021 and held it in 17 quarters.
IEQ Capital's Crescent Biopharma position peaked at $116K in Q4 2022.
30 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2025.

Based on IEQ Capital's 13F filing for Q2 2025, filed 14 Aug 2025.